We have today sent the following email:
cspencer@cochrane.org
cc
editorinchief@cochrane.org
cochrane.iag@gmail.com
gcleng@doctors.org.uk
___________________
To Catherine Spencer, Chief Executive, Cochrane
cc Karla Soares-Weiser, Editor-in-Chief
Hilda Bastian, Independent Advisory Group leader
Gillian Leng, Cochrane Governing Board member, and formerly Chief Executive of NICE
Dear Catherine Spencer,
re: Cochrane reviews of exercise therapy for CFS, now correctly called ME/CFS.
I write on behalf of the committee of the Science for ME international forum. On August 30th we sent
an open letter to Dr Soares-Weiser with copies sent to several other senior Cochrane people and to Hilda Bastian. This letter called for the immediate removal of the 2019 Larun et al review of Exercise Therapy for CFS which was acknowledged by Karla Soares-Weiser as requiring replacement at the time it was published. This flawed review continues to be cited in the development of guidelines for ME/CFS clinical care.
The letter also called for public information about the state of the process for developing a new review to replace it. Cochrane publicised this process as a flagship example of a new approach, with stakeholder involvement and engagement at its core, and a new review to be completed by early 2022. Instead there has been no public communication for two years, and not even a protocol published. Patients suffering from harmful treatment as a result of the flawed 2019 review continuing to be hosted by Cochrane are owed answers and action.
We have sent
two further open letters and set up a
petition currently signed by over 8000 people in support of our requests. The open letter also has the support of, currently,
40 ME/CFS and Long Covid organisations from around the world.
We do not find Cochrane's reply of 'this review topic is currently undergoing a process led by an Independent Advisory Group' a useful response to the concerns we have expressed. Replies from Cochrane suggest that the person delegated to reply is not aware of the issues involved.
We understand that you have had some correspondence with Caroline Struthers about this increasingly unsatisfactory situation, including concerns that the lack of action is contrary to
Cochrane's charitable objects which are primarily about the "protection and preservation of public health". We also understand that Cochrane reviews can be withdrawn if there is evidence that a treatment is ineffective and/or there is evidence of harm. The 2021 NICE ME/CFS evidence review and guideline, undertaken and completed while Gillian Leng headed NICE, documented ineffectiveness and harm from graded exercise therapy for people with ME/CFS.
People with ME/CFS have waited through 4 years of empty promises for the flawed review to be withdrawn by Cochrane. A progress report sometime on a process of unknown duration will not suffice. Suspicion grows of interference in the process, and a complete lack of understanding by Cochrane of the seriousness of the impact of this lack of action.
Can you please provide us with clear answers to the following questions:
1. Will the 2019 Larun review that Dr Soares-Weiser acknowledged was flawed four years ago be removed immediately?
2. If not, why not?
3. Who has the authority and responsibility to remove a Cochrane review that has been shown to be inaccurate and harmful?
4. Do you understand the harm that the ongoing hosting of the 2019 Larun review is causing people with ME/CFS and Long Covid?
5. The planned delivery time of the new review was early 2022. What is the new planned delivery time?
6. We understand Rachel Marshall left Cochrane last year. Who is her replacement as the 'Exercise therapy for ME/CFS' review update project manager?
_______
We look forward to your prompt answers to our questions.
This letter and any replies we receive will be published on the public Science for ME forum and copied on other media and social media as we consider appropriate.
Yours faithfully,
Trish Davis on behalf of the Science for ME committee.